Christine A Radawski (Christine Radawski, C Radawski)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Topics

Ankylosing Spondylitis

Interstitial Lung Disease

Top Venues

Scandinavian journal of rheumatology

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Ellen M Janssen, Jorien Veldwijk, Rachael L DiSantostefano, Matthias Englbrecht, Christine A Radawski, Larissa Valor-Méndez, Jennifer H Humphreys, Ian N Bruce, A Brett Hauber, Karim Raza, Marie Falahee
Acceptable risks of treatments to prevent rheumatoid arthritis among first-degree relatives: demographic and psychological predictors of risk tolerance. RMD open 8 (2) (2023)
Gwenda Simons, Karin Schölin Bywall, Matthias Englbrecht, E C Johansson, Rachael L DiSantostefano, Christine A Radawski, Jorien Veldwijk, Karim Raza, Marie Falahee
Exploring preferences of at-risk individuals for preventive treatments for rheumatoid arthritis. Scandinavian journal of rheumatology (2022)
Christine A Radawski, Tarek A Hammad, Susan Colilla, Paul Coplan, Kenneth Hornbuckle, Emily Freeman, Meredith Y Smith, Rachel E Sobel, Priya Bahri, Ariel E Arias, Dimitri Bennett
The utility of real-world evidence for benefit-risk assessment, communication, and evaluation of pharmaceuticals: Case studies. Pharmacoepidemiology and drug safety 29 (12) (2020)